Holmium-166 therapy of malignant and benign diseases.
Materials science forum, 315-317257-261, 1999
Materials science forum
Holmium-166 (Ho-166), one of the lanthanide radionuclides and produced upon neutron irradiation of naturally abundant Ho-165, is an almost ideal radionuclide for therapeutic purposes. The reasons for this are; 1) it is a strong beta emitter (Emax = 1.86 MeV) with maximum range in soft-tissue of 8.4mm, 2) it has a short physical half-life of 26.9 hours, 3) it emits a gamma photon (81 keV, 5.4%) that can be used for external imaging of post-therapy monitoring purpose. Clinical trials of Ho-166 therapy for various malignancies and benign conditions are under way in Korea, 166Ho(NO3) solution is applied into the balloon following percutaneous transfemoral coronary angioplasty (PTCA) in an attempt to inhibit neointimal hyperplasia incident to ballooning injury. Chitosan obtained by deacetylation of naturally abundant Chitin is complexed with Ho-166 by mixing acidic Chitosan solution at a room temperature with higher than 99% labelling yield. The Ho-166 complex is stable in vitro and vivo. Another benign condition, rheumatoid joint disease, is treated by local administration of the agent into the knee joint for radionuclide synovectomy. Malignant conditions being treated with Ho-166-CHICO (Chitosan complex) include cystic brain tumours, malignant ascites and pleural effusion, hepatocellular carcinomas, recurrent melanoma and recurrent rectal carcinomas. Our clinical experience with Ho-166 or Ho-166-CHICO therapy is presented.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
Total Visit :2,788,178
Total Download :1,136,909
Today View :260
Ajou University Medical Information & Media Center 164 Worldcup-ro Yeongtong-gu Suwon 16499 Korea / TEL : 031-219-5312 / FAX : 031-219-5314 Copyright (c) Ajou University Medical Information & Media Center All Rights Reserved. AJOU Open Repository는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.